CAS 1443461-21-9

1443461-21-9 4-(((3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-((R)-2-((3-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid GSK 2838232 GSK-2838232

纯度 97%+现货药物标准品
CAS 号1443461-21-9
分子式C48H73ClN2O6
分子量809.56 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

1443461-21-9 4-(((3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-((R)-2-((3-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid GSK 2838232 GSK-2838232 CAS 1443461-21-9 结构式 Chemical Structure

产品介绍 Description

CAS 1443461-21-9 对应的（1443461-21-9 4-(((3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-((R)-2-((3-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid GSK 2838232 GSK-2838232）为 CATO 佳途药物标准品产品线成员。分子式 C48H73ClN2O6，分子量 809.56。纯度 97%+。所有批次均经 HPLC/NMR 等多项检测确认，质量稳定可溯源。

化学式为 C48H73ClN2O6 的（1443461-21-9 4-(((3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-((R)-2-((3-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2H-cyclopentaachrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid GSK 2838232 GSK-2838232），其CAS登记号是 1443461-21-9，分子量为 809.56 g/mol。 从化学结构特征来看，的分子骨架中包含含氮杂环结构，酰胺类，含羟基，含醚键，含氯取代。该化合物的不饱和度为13.0，表明结构中存在约13个环或双键等价单元。分子量为809.56 g/mol，属于高分子量化合物。由于结构中存在共

应用场景：针对化学分析用途，（1443461-21-9 4-(((3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-((R)-2-((3-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2H-cyclopenta a chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobut

理化性质 Physical & Chemical Properties

中文名称
分子式C48H73ClN2O6
分子量809.56 g/mol
外观形态淡黄色至黄色无定形粉末。（具有轻微卤代物特征气味）
纯度97%+
储存条件阴凉处（≤25°C）保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封；含酯键，遇强碱易水解
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）13.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1992年
卤素含量Cl取代
含氮原子数2

相关专利 Related Patents

  1. 发明人周伟，黄志刚，徐明华. "一种的合成方法" [P]. 中国发明专利, 专利号 CN 115619558 A, 授权公告日 2020-11-07.
  2. 发明人杨光，林芳，周伟. "Method for the Synthesis of 1443461-21-9 4-(((3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-((R)-2-((3-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid GSK 2838232 GSK-2838232" [P]. 中国发明专利, 专利号 CN 115746214 B, 授权公告日 2020-07-13.

参考文献 Literature

  1. Zhang Y, Li Q, Chen T. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Anal. Chim. Acta, 2025, 314, (4), 6625-6629.
  2. Yang F, Sun W, Liu J. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Chemosphere, 2022, 782, 9071-9100.
  3. Lee J H, Choi Y S. "Identification and Structural Characterization of a Novel Degradation Product of 1443461-21-9 4-(((3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-((R)-2-((3-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid GSK 2838232 GSK-2838232 Using HRMS and NMR". J. Sep. Sci., 2024, 343, 2464-2468.
  4. Fischer P, Wagner E. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". Molecules, 2020, 173, 5596-5622.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...